Page 30 - pest-POSTEN nr 2, 2021

-pest-POSTEN Side 30

resistensbestemmelse av cefiderocol gjøres 2. Portsmouth S, van Veenhuyzen D, Echols R
ved alle laboratorier. AFA har i sine anbefalte et al. Cefiderocol versus imipenem-cilastatin
resistenspaneler inkludert cefiderocol som et for the treatment of complicated urinary
av reservemidlene for resistensbestemmelse av tract infections caused by Gram-negative
multiresistente stammer av Enterobacterales, uropathogens: a phase 2, randomised,
Pseudomonas og Acinetobacter. Norske double-blind, non-inferiority trial. Lancet
laboratorier bør derfor inkludere cefiderocol i Infect Dis. 2018;18(12):1319-28.
sine resistenspaneler. 3. Wunderink RG, Matsunaga Y, Ariyasu M et
Kilder og nyttig lesing: al. Cefiderocol versus high-dose, extended-
infusion meropenem for the treatment of
El-Lababidi: Oversiktsartikkel om cefiderocol Gram-negative nosocomial pneumonia
(5). (APEKS-NP): a randomised, double-blind,
Cefiderocol: the Trojan horse has arrived but will phase 3, non-inferiority trial. Lancet Infect
Troy fall?(6). Dis. 2021;21(2):213-25.
NICE Antimicrobial prescribing: cefiderocol. 4. Iregui A, Khan Z, Landman D, Quale
Evidence review J. Activity of Cefiderocol Against
Enterobacterales, Pseudomonas aeruginosa,
and Acinetobacter baumannii Endemic to
Referanser: Medical Centers in New York City. Microb
1. Bassetti M, Echols R, Matsunaga Y et al. Drug Resist. 2020;26(7):722-6.
Efficacy and safety of cefiderocol or best 5. El-Lababidi RM, Rizk JG. Cefiderocol:
available therapy for the treatment of serious A Siderophore Cephalosporin. Ann
infections caused by carbapenem-resistant Pharmacother. 2020;54(12):1215-31.
Gram-negative bacteria (CREDIBLE-CR):
a randomised, open-label, multicentre, 6. Heil EL, Tamma PD. Cefiderocol: the Trojan
pathogen-focused, descriptive, phase 3 trial. horse has arrived but will Troy fall? Lancet
Lancet Infect Dis. 2021;21(2):226-40. Infect Dis. 2021;21(2):153-5.

Illustrasjon: Shutterstock